Discovery and saturation analysis of cancer genes across 21 tumour types
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, the dysregulation of chromatin looping may be causally related to carcinogenesis (Extended Data Fig. 7a) 31,32.”
From The structural basis for cohesin–CTCF-anchored loops (2020) · cites this paper as [31]
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“The process of tumor development is strongly related to the dysfunctions caused by TP53 mutations.3,4”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
In the citing paper
“Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“(5) Chromatin regulation—Five genes are associated with chromatin regulation.”
Self-citationMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053 · cited 1×
“(4) Genome stability—Six genes encode proteins related to genome stability.”
BackgroundSelf-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870 · cited 1×
“(7) RNA processing—Three genes are associated with RNA processing and metabolism.”
BackgroundSelf-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 4×
“We ask: (1) Can large-scale genomic analysis across tumor types reliably identify all known cancer genes? (2) Will it reveal many new candidate cancer genes? (3) How far do we stand from having a complete catalog of cancer genes – at least those of intermediate frequency? We used rigorous statistical methods to enumer…”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 401–500 of 1,017
A first-generation pediatric cancer dependency map
Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhayay, P., Wechsler, C. S., Fung, I., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00819-w · Cited by 153
Self-citationLiquori, A., Ibáñez, M., Sargas, C., Sanz, M. Á., Barragán, E., & Cervera, J. (2020) · Cancers · doi:10.3390/cancers12030624 · Cited by 159
“A wide number of genomic alterations have been associated with APL, but only some of them occur recurrently [115–117].”
BackgroundThe Genomic Landscape of Male Breast Cancers
Piscuoglio, S., Ng, C. K. Y., Murray, M. P., Guerini‐Rocco, E., Martelotto, L. G., Geyer, F. C., Bidard, F., Berman, S., Fusco, N., Sakr, R. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2840 · Cited by 172
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
Liu, D., Abbosh, P., Keliher, D., Reardon, B., Miao, D., Mouw, K., Weiner-Taylor, A., Wankowicz, S., Han, G., Teo, M. Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02320-7 · Cited by 151
Self-citationThe Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer
Krogan, N. J., Lippman, S., Agard, D. A., Ashworth, A., & Ideker, T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.008 · Cited by 149
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation
Gingras, M., Covington, K. R., Chang, D. K.-F., Donehower, L. A., Gill, A. J., Ittmann, M., Creighton, C. J., Johns, A. L., Shinbrot, E., Dewal, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.005 · Cited by 156
“This mutation frequency is three times higher than in any other cancer (Table S3D) (Cerami et al., 2012; Gao et al., 2013; Lawrence et al., 2014) (http://www.”
BackgroundCellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 195
Cheng, F., Zhao, J., & Zhao, Z. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv068 · Cited by 161
McMahon, M., Contreras, A., & Ruggero, D. (2015) · WIREs RNA · doi:10.1002/wrna.1266 · Cited by 147
Rogers, Z. N., McFarland, C. D., Winters, I. P., Naranjo, S., Chuang, C.-H., Petrov, D., & Winslow, M. M. (2017) · Nature Methods · doi:10.1038/nmeth.4297 · Cited by 147
“While many putative tumor suppressors have been identified from cancer genome sequencing, limited strategies exist to test their function in vivo in a rapid, systematic, and quantitative manner (Supplementary Table 1) 1,2,4,7,20,31 .”
Precision medicine in pediatric oncology
Forrest, S. J., Geoerger, B., & Janeway, K. A. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000570 · Cited by 179
Guo, Y. A., Chang, M. M., Huang, W., Ooi, W. F., Xing, M., Tan, P., & Skanderup, A. J. (2018) · Nature Communications · doi:10.1038/s41467-018-03828-2 · Cited by 148
Deep whole-genome analysis of 494 hepatocellular carcinomas
Chen, L., Zhang, C., Xue, R., Liu, M., Bai, J., Bao, J., Wang, Y., Jiang, N., Li, Z., Wang, W., et al. (2024) · Nature · doi:10.1038/s41586-024-07054-3 · Cited by 148
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Guièze, R., & Wu, C. J. (2015) · Blood · doi:10.1182/blood-2015-02-585042 · Cited by 148
Bradley, W. D., Arora, S., Busby, J., Balasubramanian, S., Gehling, V. S., Nasveschuk, C. G., Vaswani, R. G., Yuan, C.-C., Hatton, C., Zhao, F., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.017 · Cited by 159
“Chromatin modifier-encoding genes are now appreciated to be frequently targeted by genomic aberrations in cancer (Garraway and Lander, 2013; Gonzalez-Perez et al., 2013; Lawrence et al., 2014; Zack et al., 2013).”
BackgroundTumour heterogeneity poses a significant challenge to cancer biomarker research
Cyll, K., Ersvær, E., Vlatkovic, L., Pradhan, M., Kildal, W., Kjær, M. A., Kleppe, A., Hveem, T. S., Carlsen, B., Gill, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.171 · Cited by 156
“Tumour heterogeneity is a well-known trait of most cancers (Lawrence et al, 2014; Andor et al, 2015).”
BackgroundA catalogue of somatic NRF2 gain-of-function mutations in cancer
Kerins, M. J., & Ooi, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31281-0 · Cited by 140
Karlstaedt, A., Zhang, X., Vitrac, H., Harmancey, R., Vasquez, H., Wang, J. H., Goodell, M. A., & Taegtmeyer, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601650113 · Cited by 158
G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
Arang, N., & Gutkind, J. S. (2020) · FEBS Letters · doi:10.1002/1873-3468.14017 · Cited by 157
Towards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 165
“…while some genetic aberrations occur at high frequency in specific cancer types, many tumours exhibit a “long tail” distribution of rare alterations that are difficult to recognize in modestly sized patient cohorts, and are hard to qualify as driver genes rather than random passenger mutations 7 .”
Briere, D. M., Sudhakar, N., Woods, D. M., Hallin, J. F., Engstrom, L. D., Aranda, R., Chiang, H., Sodré, A. L., Olson, P., Weber, J. S., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2091-y · Cited by 158
O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle
Hanover, J. A., Chen, W., & Bond, M. R. (2018) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-018-9751-2 · Cited by 156
Yan, T., Cui, H., Zhou, Y., Yang, B. J., Kong, P., Zhang, Y., Liu, Y., Wang, B., Cheng, Y., Li, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09255-1 · Cited by 155
Cancer Immunoediting in the Era of Immuno-oncology
Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 184
Diverse Epigenetic Mechanisms of Human Disease
Brookes, E., & Shi, Y. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092518 · Cited by 142
Functions of SMARCAL1, ZRANB3, and HLTF in maintaining genome stability
Poole, L. A., & Cortez, D. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1380597 · Cited by 141
“metrial cancers suggest it may function as a tumor suppressor (Lawrence et al. 2014).”
BackgroundBET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yokoyama, Y., Zhu, H., Lee, J., Kossenkov, A. V., Wu, S. Y., Wickramasinghe, J. M., Yin, X., Palozola, K. C., Gardini, A., Showe, L. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0854 · Cited by 157
Rubin, M. A., Bristow, R. G., Thienger, P., Dive, C., & Imielinski, M. B. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.033 · Cited by 147
Acute depletion of CTCF directly affects MYC regulation through loss of enhancer–promoter looping
Hyle, J., Zhang, Y., Wright, S., Xu, B., Shao, Y., Easton, J., Tian, L., Feng, R., Xu, P., & Li, C. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz462 · Cited by 139
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Sworder, B. J., Kurtz, D. M., Alig, S., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Esfahani, M. S., Olsen, M. N., Hamilton, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.005 · Cited by 158
Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid Tumors
Dienstmann, R., Jang, I. S., Bot, B., Friend, S., & Guinney, J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1118 · Cited by 139
Hierarchical HotNet: identifying hierarchies of altered subnetworks
Reyna, M. A., Leiserson, M. D. M., & Raphael, B. J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty613 · Cited by 138
Single nucleotide variations: Biological impact and theoretical interpretation
Katsonis, P., Koire, A., Wilson, S. J., Hsu, T., Lua, R. C., Wilkins, A. D., & Lichtarge, O. (2014) · Protein Science · doi:10.1002/pro.2552 · Cited by 137
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines
Martin, S. D., Brown, S. D., Wick, D. A., Nielsen, J. S., Kroeger, D. R., Twumasi-Boateng, K., Holt, R. A., & Nelson, B. H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0155189 · Cited by 137
Yamauchi, T., Masuda, T., Canver, M. C., Seiler, M., Semba, Y., Shboul, M., Al-Raqad, M., Maeda, M., Schoonenberg, V. A. C., Cole, M. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.012 · Cited by 138
“Our w inhibitors for AML therapy. needed therapies, functional studies are necessary to assess the significance of AML-associated mutations (Boehm and Hahn, 2011; Garraway and Lander, 2013; Lawrence et al., 2014).”
BackgroundColli, L. M., Machiela, M. J., Myers, T. A., Jessop, L., Yu, K., & Chanock, S. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0170 · Cited by 137
Pearson, A., Proszek, P., Pascual, J., Fribbens, C., Shamsher, M. K., Kingston, B., O'Leary, B., Herrera-Abreu, M. T., Cutts, R. J., Garcia-Murillas, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4044 · Cited by 136
He, X., Chen, X., Zhang, X., Duan, X., Pan, T., Hu, Q., Zhang, Y., Zhong, F., Liu, J., Zhang, H., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv214 · Cited by 136
Piscuoglio, S., Ng, C. K. Y., Murray, M. P., Burke, K. A., Edelweiss, M., Geyer, F. C., Macedo, G. S., Inagaki, A., Papanastasiou, A. D., Martelotto, L. G., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4672 · Cited by 145
Tao, S., Rojo de la Vega, M., Chapman, E., Ooi, A., & Zhang, D. D. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22745 · Cited by 135
DriverML: a machine learning algorithm for identifying driver genes in cancer sequencing studies
Han, Y., Yang, J., Qian, X., Cheng, W.-C., Liu, S.-H., Hua, X., Zhou, L., Yang, Y., Wu, Q., Liu, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz096 · Cited by 136
“Therefore, we estimated general functional weights without regard to cancer types using all the non-TCGA pan-cancer datasets from ICGC and previous studies (32–34).”
BackgroundMethodInfluentialEvolution of delayed resistance to immunotherapy in a melanoma responder
Liu, D., Lin, J., Robitschek, E. J., Kasumova, G. G., Heyde, A., Shi, A., Kraya, A., Zhang, G., Moll, T. O. C., Frederick, D. T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01331-8 · Cited by 148
“We removed 6 tumors due to low tumor purity ( 10% tumor cells and no matched mutations in significantly mutated genes 50,51 ), yielding 37 total tumor samples + 1 matched blood normal for analysis.”
Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies
Lee, J.-K., Choi, Y.-L., Kwon, M., & Park, P. J. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044446 · Cited by 135
Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice
Rogers, Z. N., McFarland, C. D., Winters, I. P., Seoane, J. A., Brady, J. J., Yoon, S., Curtis, C., Petrov, D. A., & Winslow, M. M. (2018) · Nature Genetics · doi:10.1038/s41588-018-0083-2 · Cited by 132
The mini-driver model of polygenic cancer evolution
Castro-Giner, F., Ratcliffe, P. J., & Tomlinson, I. P. M. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3999 · Cited by 149
Cescon, D. W., Haibe-Kains, B., & Mak, T. W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424869112 · Cited by 134
Notch Activation as a Driver of Osteogenic Sarcoma
Tao, J., Jiang, M.-M., Jiang, L., Salvo, J. S., Zeng, H.-C., Dawson, B., Bertin, T. K., Rao, P. H., Chen, R., Donehower, L. A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.023 · Cited by 134
“Notch gain-of-function mutations have also been found in several types of solid tumors, including lung cancer (Lawrence et al., 2014; Westhoff et al., 2009).”
BackgroundEnrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
Padovan-Merhar, O. M., Raman, P., Ostrovnaya, I., Kalletla, K., Rubnitz, K. R., Sanford, E. M., Ali, S. M., Miller, V. A., Mossé, Y. P., Granger, M. P., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006501 · Cited by 135
Kamel, H. F. M., & Al-Amodi, H. S. A. B. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.11.005 · Cited by 157
A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces
Porta-Pardo, E., Garcia-Alonso, L., Hrabe, T., Dopazo, J., & Godzik, A. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004518 · Cited by 133
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Maura, F., Rajanna, A. R., Ziccheddu, B., Poos, A. M., Derkach, A., Maclachlan, K., Durante, M., Diamond, B., Papadimitriou, M., Davies, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01277 · Cited by 131
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise
Kim, J., Akbani, R., Creighton, C. J., Lerner, S. P., Weinstein, J. N., Getz, G. A., & Kwiatkowski, D. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1215 · Cited by 147
Self-citationCancer-mutation network and the number and specificity of driver mutations
Iranzo, J., Martincorena, I., & Koonin, E. V. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803155115 · Cited by 152
Shaping the cellular landscape with Set2/SETD2 methylation
McDaniel, S. L., & Strahl, B. D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2517-x · Cited by 136
Zhao, Y., Feng, X., Chen, Y., Selfridge, J. E., Gorityala, S., Du, Z., Wang, J. M., Hao, Y., Cioffi, G., Conlon, R. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0600 · Cited by 129
Cancer driver mutations: predictions and reality
Ostroverkhova, D. S., Przytycka, T. M., & Panchenko, A. R. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.03.007 · Cited by 161
Nussinov, R., Jang, H., Tsai, C.-J., & Cheng, F. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006658 · Cited by 130
The landscape of driver mutations in cutaneous squamous cell carcinoma
Chang, D., & Shain, A. H. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00226-4 · Cited by 157
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129
de Miranda, N. F. C. C., Georgiou, K., Chen, L., Wu, C., Gao, Z., Zaravinos, A., Lisboa, S., Enblad, G., Teixeira, M. R., Zeng, Y., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546309 · Cited by 129
e-Driver: a novel method to identify protein regions driving cancer
Porta-Pardo, E., & Godzik, A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu499 · Cited by 130
“We then again corrected for multiple testing by considering as positive only those PFRs with a Q-value 5 0.05.”
MethodInfluentialGenomic landscape of intracranial meningiomas
Bi, W. L., Abedalthagafi, M., Horowitz, P. M., Agarwalla, P. K., Mei, Y., Aizer, A. A., Brewster, R., Dunn, G. P., Al‐Mefty, O., Alexander, B. M., et al. (2016) · Journal of neurosurgery · doi:10.3171/2015.6.jns15591 · Cited by 131
Cohesin mutations in human cancer
Hill, V. K., Kim, J.-S., & Waldman, T. A. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.05.002 · Cited by 152
“analysis of TCGA data from 12 major cancer types identified STAG2 as one of only 12 genes that were significantly mutated in four or more cancer types [78].”
Giannikou, K., Malinowska, I. A., Pugh, T. J., Yan, R., Tseng, Y.-Y., Oh, C., Kim, J., Tyburczy, M. E., Chekaluk, Y., Liu, Y., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006242 · Cited by 129
Self-citationInsertions and Deletions Target Lineage-Defining Genes in Human Cancers
Imielinski, M., Guo, G., & Meyerson, M. (2017) · Cell · doi:10.1016/j.cell.2016.12.025 · Cited by 129
“, 2012) and MutSigCV (Lawrence et al., 2014) have been developed to correct for the mutational heterogeneity that otherwise results in the nomination of spurious hotspots in late-replicating and poorly expressed genes.”
InfluentialSelf-citationNon-coding driver mutations in human cancer
Elliott, K., & Larsson, E. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00371-z · Cited by 166
Analysis of somatic microsatellite indels identifies driver events in human tumors
Maruvka, Y. E., Mouw, K. W., Karlic, R., Parasuraman, P., Kamburov, A., Polak, P., Haradhvala, N. J., Hess, J. M., Rheinbay, E., Brody, Y., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3966 · Cited by 128
Self-citationEffect Sizes of Somatic Mutations in Cancer
Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy168 · Cited by 135
Wu, S., Fukumoto, T., Lin, J., Nacarelli, T., Wang, Y., Ong, D., Liu, H., Fatkhutdinov, N., Zundell, J. A., Karakashev, S. V., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00160-x · Cited by 143
Improving cancer driver gene identification using multi-task learning on graph convolutional network
Peng, W., Tang, Q., Dai, W., & Chen, T. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab432 · Cited by 142
PI3Kβ controls immune evasion in PTEN-deficient breast tumours
Bergholz, J. S., Wang, Q., Wang, Q., Ramseier, M. L., Prakadan, S. M., Wang, W., Fang, R., Kabraji, S. K., Zhou, Q., Gray, G. K., et al. (2023) · Nature · doi:10.1038/s41586-023-05940-w · Cited by 152
Schmidt, K. T., Chau, C. H., Price, D. K., & Figg, W. D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.765 · Cited by 126
Murakami, R., Matsumura, N., Brown, J. B., Higasa, K., Tsutsumi, T., Kamada, M., Abou-Taleb, H., Hosoe, Y., Kitamura, S., Yamaguchi, K. D., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.06.012 · Cited by 150
Zhang, X., Choi, P. S., Francis, J. M., Gao, G. F., Campbell, J. D., Ramachandran, A., Mitsuishi, Y., Ha, G., Shih, J., Vazquez, F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0532 · Cited by 126
Self-citationColorectal Cancer and Metabolism
Brown, R. E., Short, S. P., & Williams, C. S. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0420-y · Cited by 147
Tassan, N. A. A., Whiffin, N., Hosking, F. J., Palles, C., Farrington, S. M., Dobbins, S. E., Harris, R. C., Gorman, M., Tenesa, A., Meyer, B. F., et al. (2015) · Scientific Reports · doi:10.1038/srep10442 · Cited by 138
“The frequency of somatic mutations in CRC was obtained using the CBioPortal for Cancer Genomics 39,40 and TumorPortal web servers 41 .”
Meyer, M. J., Lapcevic, R., Romero, A. E., Yoon, M., Das, J., Beltrán, J. F., Mort, M., Stenson, P. D., Cooper, D. N., Paccanaro, A., et al. (2016) · Human Mutation · doi:10.1002/humu.22963 · Cited by 125
Prickett, T. D., Crystal, J. S., Cohen, C. J., Pasetto, A., Parkhurst, M. R., Gartner, J. J., Yao, X., Wang, R., Gros, A., Li, Y. F., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0215 · Cited by 126
The evolving genomic landscape of urothelial carcinoma
Glaser, A. P., Fantini, D., Shilatifard, A., Schaeffer, E. M., & Meeks, J. J. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.11 · Cited by 134
Genomic profiling reveals mutational landscape in parathyroid carcinomas
Pandya, C., Uzilov, A. V., Bellizzi, J., Lau, C. Y., Moe, A. S., Strahl, M., Hamou, W., Newman, L. C., Fink, M. Y., Antipin, Y., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92061 · Cited by 136
Foulkes, W. D., Clarke, B. A., Hasselblatt, M., Majewski, J., Albrecht, S., & McCluggage, W. G. (2014) · The Journal of Pathology · doi:10.1002/path.4362 · Cited by 125
Uterine adenosarcomas are mesenchymal neoplasms
Piscuoglio, S., Burke, K. A., Ng, C. K. Y., Papanastasiou, A. D., Geyer, F. C., Macedo, G. S., Martelotto, L. G., de Bruijn, I., Filippo, M. R. D., Schultheis, A. M., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4675 · Cited by 129
Sun, X., Clermont, P., Jiao, W., Helgason, C. D., Gout, P. W., Wang, Y. Z., & Qu, S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30133 · Cited by 132
Apoptosis Initiation Through the Cell-Extrinsic Pathway
Nair, P. M., Lu, M., Petersen, S., & Ashkenazi, A. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-417158-9.00005-4 · Cited by 154
Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts
van der Lelij, P., Lieb, S., Jude, J., Wutz, G., Santos, C. P., Falkenberg, K., Schlattl, A., Ban, J., Schwentner, R., Hoffmann, T., et al. (2017) · eLife · doi:10.7554/elife.26980 · Cited by 124
The value of cell‐free DNA for molecular pathology
Stewart, C. M., Kothari, P. D., Mouliere, F., Mair, R., Somnay, S., Benayed, R., Zehir, A., Weigelt, B., Dawson, S., Arcila, M. E., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5048 · Cited by 125
CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers
Tokheim, C., & Karchin, R. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.005 · Cited by 124
An integrative analysis of the age-associated multi-omic landscape across cancers
Chatsirisupachai, K., Lesluyes, T., Paraoan, L., Van Loo, P., & de Magalhães, J. P. (2021) · Nature Communications · doi:10.1038/s41467-021-22560-y · Cited by 122
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 138
Defining actionable mutations for oncology therapeutic development
Carr, T. H., McEwen, R. K., Dougherty, B. A., Johnson, J. H., Dry, J. R., Lai, Z., Ghazoui, Z. F., Laing, N. M., Hodgson, D., Cruzalegui, F. H., et al. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.35 · Cited by 143
Lin, D., Dinh, H. Q., Xie, J., Mayakonda, A., Silva, T. C., Jiang, Y., Ding, L., He, J., Xu, X., Hao, J., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-314607 · Cited by 130
The NOTCH Pathway in Head and Neck Squamous Cell Carcinoma
Fukusumi, T., & Califano, J. A. (2018) · Journal of Dental Research · doi:10.1177/0022034518760297 · Cited by 132
DAXX in cancer: phenomena, processes, mechanisms and regulation
Mahmud, I., & Liao, D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz634 · Cited by 130
Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss
Gross, A. M., Orosco, R. K., Shen, J. P., Egloff, A. M., Carter, H. K., Hofree, M., Choueiri, M., Coffey, C. S., Lippman, S. M., Hayes, D. N., et al. (2014) · Nature Genetics · doi:10.1038/ng.3051 · Cited by 138
Takeda, H., Wei, Z., Koso, H., Rust, A. G., Yew, C. C. K., Mann, M. B., Ward, J. M., Adams, D. J., Copeland, N. G., & Jenkins, N. A. (2015) · Nature Genetics · doi:10.1038/ng.3175 · Cited by 132
Jha, D. K., & Strahl, B. D. (2014) · Nature Communications · doi:10.1038/ncomms4965 · Cited by 123
Gollner, A., Rudolph, D., Arnhof, H., Bauer, M., Blake, S. M., Boehmelt, G., Cockroft, X.-L., Dahmann, G., Ettmayer, P., Gerstberger, T., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00900 · Cited by 121
The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types
Fancello, L., Kampen, K. R., Hofman, I. J. F., Verbeeck, J., & Keersmaecker, K. D. (2017) · Oncotarget · doi:10.18632/oncotarget.14895 · Cited by 122
Bayesian inference of negative and positive selection in human cancers
Weghorn, D., & Sunyaev, S. R. (2017) · Nature Genetics · doi:10.1038/ng.3987 · Cited by 136
Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Venue
- Nature
- Published
- 2014-01
- Volume
- 505
- Issue
- 7484
- Pages
- 495-501
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4048962
- OpenAlex
- W2114031931
- Cited by
- 3,096
- References
- 13
- Citations by year
- 2026: 103 · 2025: 188 · 2024: 202 · 2023: 223 · 2022: 235 · 2021: 241 · 2020: 277 · 2019: 268 · 2018: 264 · 2017: 312 · 2016: 305 · 2015: 291 · 2014: 177
- FWCI
- 116.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R01CA157304)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- cancer genes, somatic point mutations, cancer types, saturation analysis, mutation frequency, exome sequencing, sample size determination, mutation rate heterogeneity, cancer genomics
- MeSH terms
- Chromatin, DNA Mutational Analysis, Humans, Neoplasms, RNA Processing, Post-Transcriptional, Genome, Human, Case-Control Studies, Apoptosis, Point Mutation, Sample Size, Genomics, Genomic Instability, Cell Proliferation, Genes, Neoplasm, Immune Evasion, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.